Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CBLB | Q13191 | 6/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21024564 | 0.97 | DDB1 (0.34) | DDB1CRBNFPR1FPR2PRKDC | |
| SCHEMBL21024549 | 0.89 | FPR1 (0.34) | DDB1CRBNFPR1FPR2PRKDC | |
| SCHEMBL21024574 | 0.87 | LRRK2 (0.35) | FPR1FPR2PRKDCCBLBALDH1A1 | |
| SCHEMBL21024548 | 0.86 | FPR1 (0.34) | FPR1FPR2PRKDCCBLBALDH1A1 | |
| SCHEMBL21024568 | 0.86 | FPR1 (0.32) | DDB1CRBNFPR1FPR2PRKDC | |
| SCHEMBL24612137 | 0.84 | CBLB (0.42) | CBLB | |
| SCHEMBL20098157 | 0.84 | CBLB (0.42) | CBLB | |
| SCHEMBL20098514 | 0.83 | CBLB (0.44) | CBLB | |
| SCHEMBL20985164 | 0.79 | CBLB (0.33) | DDB1CRBNFPR1FPR2PRKDC | |
| SCHEMBL20985177 | 0.79 | CBLB (0.33) | DDB1CRBNFPR1FPR2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | AZI2, FURIN, ACE2 | DDB1 4573/4885CRBN 2108/4885FPR1 244/4885 |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | AZI2, FURIN, ACE2 | DDB1 4573/4885CRBN 2108/4885FPR1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.